SciVision Biotech Inc.?s products, hyaluronic acid synovial fluid supplement ?Flexotron Solo?(2.2%)and ?Flexotron Magnum?(3%) have obtained medical device licenses. Date of occurrence of the event: April 10, 2024. Cause of occurrence: Hyaluronic acid synovial fluid supplement ?Flexotron Solo?(2.2%)and?Flexotron Magnum?(3%), developed and produced by the company, have obtained the medical device licenses (P3H 2022/17103).

Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings a significant impact on shareholders rights or the price of the securities on public companies.): This product contains linear hyaluronic acid, which can increase joint lubrication and reduce joint friction. For the patients with osteoarthritis, it can decrease the degeneration rate of cartilage, enhance its metabolism, relieve pain and discomfort, improve daily activities and increase range of motion of joints. The company has obtained these two Russian medical device licenses, which can increase the sales performance in the Russian market and contribute to the company's revenue.